Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00074668" target="_blank" >RIV/00216224:14110/14:00074668 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/14:00061310 RIV/00159816:_____/14:00061310

Výsledek na webu

<a href="http://dx.doi.org/10.1515/cclm-2012-0833" target="_blank" >http://dx.doi.org/10.1515/cclm-2012-0833</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1515/cclm-2012-0833" target="_blank" >10.1515/cclm-2012-0833</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality

Popis výsledku v původním jazyce

Background: We hypothesized that genetic variability in genes encoding enzymes metabolizing glycolytic intermediates produced in excess under hyperglycemic conditions [i.e., transketolase ( TKT ), transaldolase, TKT-like protein 1, fructosamine 3-kinase( FN3K ), glyoxalase 1 and glucose-6-phosphate dehydrogenase] could influence progression of diabetic nephropathy (DN) and diabetesrelated morbidity and mortality. Methods: A total of 19 single nucleotide polymorphisms (SNPs) in six candidate genes werestudied in 314 type 2 diabetic subjects with variable stage of kidney disease (normo- and microalbuminuria, proteinuria, end-stage renal disease). SNP selection criteria were based on known functional effect and gene coverage. SNPs were detected using polymerase chain reaction based methods. Subjects were followed up for median of 38 months. Time-to-event analysis considered three end-points: 1) DN progression by at least one stage; 2) major cardiovascular event; and 3) all-cause mortali

Název v anglickém jazyce

Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality

Popis výsledku anglicky

Background: We hypothesized that genetic variability in genes encoding enzymes metabolizing glycolytic intermediates produced in excess under hyperglycemic conditions [i.e., transketolase ( TKT ), transaldolase, TKT-like protein 1, fructosamine 3-kinase( FN3K ), glyoxalase 1 and glucose-6-phosphate dehydrogenase] could influence progression of diabetic nephropathy (DN) and diabetesrelated morbidity and mortality. Methods: A total of 19 single nucleotide polymorphisms (SNPs) in six candidate genes werestudied in 314 type 2 diabetic subjects with variable stage of kidney disease (normo- and microalbuminuria, proteinuria, end-stage renal disease). SNP selection criteria were based on known functional effect and gene coverage. SNPs were detected using polymerase chain reaction based methods. Subjects were followed up for median of 38 months. Time-to-event analysis considered three end-points: 1) DN progression by at least one stage; 2) major cardiovascular event; and 3) all-cause mortali

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

ED - Fyziologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13198" target="_blank" >NT13198: Pentózový cyklus jako potenciální nový terapeutický cíl v prevenci diabetických komplikací</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Chemistry and Laboratory Medicine

ISSN

1434-6621

e-ISSN

—

Svazek periodika

52

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

7

Strana od-do

77-83

Kód UT WoS článku

000328687600011

EID výsledku v databázi Scopus

—